CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 6,967 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total transaction of $366,324.86. Following the completion of the transaction, the chief executive officer directly owned 226,106 shares in the company, valued at $11,888,653.48. This trade represents a 2.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Samarth Kulkarni also recently made the following trade(s):

• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $51.75, for a total transaction of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Stock Down 2.2%

CRSP opened at $53.46 on Monday. The company has a market capitalization of $5.13 billion, a PE ratio of -8.20 and a beta of 1.72. The firm has a 50-day simple moving average of $53.84 and a two-hundred day simple moving average of $57.24. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The firm had revenue of $0.86 million during the quarter, compared to the consensus estimate of $4.72 million. During the same period last year, the firm posted ($1.01) earnings per share. The company’s revenue for the quarter was down 97.8% compared to the same quarter last year. As a group, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Trending Headlines about CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Pipeline and earnings reaction — MarketBeat notes investors cheered Q4 results for pipeline progress and CASGEVY adoption (cash runway ~ $1.9B, CTX611 upside). That optimism helped the stock rebound after earnings even though reported revenue was small due to revenue-sharing with Vertex. CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
• Positive Sentiment: Bull case on long-term upside — Seeking Alpha highlights a “Buy” thesis driven by CASGEVY launch economics and CTX611 potential (modeled high peak sales), arguing significant upside exists despite high risk. Crispr Therapeutics: Very High Risk But Even Higher Potential Reward
• Neutral Sentiment: Short-interest data ambiguous — reported short interest entries show zero shares/NaN changes and a 0.0 days ratio, which appears to be a reporting artifact rather than meaningful positioning information. No clear short-squeeze or build-up signal.
• Neutral Sentiment: Reassessment pieces — coverage (Yahoo) asks whether the recent rebound warrants a rethink, reflecting mixed analyst views and technical levels to watch; useful for investors weighing timing. Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Share Price Rebound?
• Negative Sentiment: Insider selling — CEO Samarth Kulkarni and General Counsel James Kasinger sold shares on Feb 19 (CEO ~6,967 shares; GC ~2,112 shares), modestly reducing their positions. Insider sales can signal near-term caution to some investors. CEO Filing GC Filing
• Negative Sentiment: Near-term fundamentals and skepticism — Q4 showed a big EPS miss and revenue limited by a revenue-share with Vertex; some analysts (e.g., Morgan Stanley cited in coverage) remain cautious with low price targets. Pessimistic takes (Fool) question the long-term payoff versus risk. Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently made changes to their positions in the company. Mcguire Capital Advisors Inc. bought a new position in CRISPR Therapeutics during the 4th quarter valued at about $25,000. Ramirez Asset Management Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $26,000. Rothschild Investment LLC boosted its position in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after buying an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its stake in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after buying an additional 382 shares during the last quarter. Finally, Atlantic Union Bankshares Corp purchased a new stake in shares of CRISPR Therapeutics in the second quarter worth approximately $33,000. Institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on CRSP shares. Bank of America cut their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Chardan Capital increased their price objective on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research report on Saturday, February 14th. Citigroup restated a “buy” rating on shares of CRISPR Therapeutics in a report on Monday, February 16th. Wedbush lowered their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating for the company in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $64.24.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.